MA-NETSCOUT-SYSTEMS
21.9.2021 12:03:07 CEST | Business Wire | Press release
NETSCOUT SYSTEMS, INC., (NASDAQ: NTCT) today announced findings from its bi-annual Threat Intelligence Report that underscore the dramatic impact cyberattacks continue to have on private and public organizations and governments worldwide. In the first half of 2021, cybercriminals launched approximately 5.4 million Distributed Denial of Services (DDoS) attacks, increasing 11% over 1H2020 figures. Additionally, data projections from NETSCOUT's Active Level Threat Analysis System (ATLAS™) Security Engineering and Response Team (ASERT) point to 2021 as another record-setting year on track to surpass 11 million global DDoS attacks. ASERT expects this long tail of attacker innovation to last, fueling a growing cybersecurity crisis that will continue to impact public and private organizations.
In the wake of Colonial Pipeline, JBS, Harris Federation, Australian broadcaster Channel Nine, CNA Financial, and several other high-profile attacks, the impact of DDoS and other cybersecurity attacks has been felt worldwide. As a result, leading governments are introducing new programs and policies to defend against attacks, and policing organizations are initiating unprecedented collaborative efforts to address the crisis.
During 1H2021, cybercriminals weaponized and exploited seven newer reflection/amplification DDoS attack vectors putting organizations at greater risk. This attack vector explosion spurred an increase in multivector DDoS attacks with a record-setting 31 attack vectors deployed in a single attack against one organization.
Other key findings from the NETSCOUT 1H2021 Threat Intelligence Report include:
- New adaptive DDoS attack techniques evade traditional defenses. By customizing their strategies, cybercriminals evolved their attack efforts to bypass cloud-based and on-premise static DDoS defenses to target commercial banks and credit card processors.
- Connectivity supply chain increasingly under attack. Bad actors looking to cause the most collateral damage focused their efforts on vital internet components, including DNS servers, virtual private network (VPN) concentrators, services, and internet exchanges, disrupting essential gateways.
- Cybercriminals add DDoS to their toolkit to launch triple extortion campaigns. Ransomware has become big business, with extortionists adding DDoS to their attack regimen to ratchet up the pressure on victims and add stress to security teams. Triple extortion combines file encryption, data theft, and DDoS attacks, increasing the possibility that cyber criminals receive payment.
- The fastest DDoS attack recorded a 16.17% year-over-year increase. A Brazilian wireline broadband internet user launched the attack, which was likely related to online gaming. Using DNS reflection/amplification, TCP ACK flood, TCP RST flood, and TCP SYN/ACK reflection/amplification vectors, the sophisticated attack recorded 675 Mpps.
- The largest DDoS attack, 1.5 Tbps, represented a year-over-year increase of 169%. ASERT data identified this attack against a German ISP, deploying a DNS reflection/amplification vector. This attack represents a dramatic increase in size over any attacks recorded in 1H2020.
- Botnets contribute to major DDoS activity - Tracked botnet clusters and high-density attack-source zones worldwide showcased how malicious adversaries abused these botnets to participate in more than 2.8 million DDoS attacks. In addition, well-known IoT botnets Gafgyt and Mirai continue to pose a severe threat contributing to more than half of the total number of DDoS attacks.
"Cybercriminals are making front-page news launching an unprecedented number of DDoS attacks to take advantage of the pandemic's remote work shift by undermining vital components of the connectivity supply chain," stated Richard Hummel, threat intelligence lead, NETSCOUT. "Ransomware gangs added triple-extortion DDoS tactics to their repertoire. Simultaneously, the Fancy Lazarus DDoS extortion campaign kicked into high gear threatening organizations in multiple industries with a focus on ISPs and specifically their authoritative DNS servers."
NETSCOUT's Threat Intelligence Report covers the latest trends and activities in the DDoS threat landscape. It covers data secured from NETSCOUT's Active Level Threat Analysis System (ATLAS™) coupled with NETSCOUT's ATLAS Security Engineering & Response Team (ASERT) insights.
The visibility and analysis represented in the Threat Intelligence Report and Omnis® Threat Horizon fuel the ATLAS Intelligence Feed used across NETSCOUT's Omnis security product portfolio to detect and block threat activity for enterprises and service providers worldwide.
For more information on NETSCOUT's semi-annual Threat Intelligence Report, please visit our interactive website . You can also find us on Facebook , LinkedIn, and Twitter for threat updates and the latest trends and insights.
About NETSCOUT
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) helps assure digital business services against security, availability, and performance disruptions. Our market and technology leadership stems from combining our patented smart data technology with smart analytics. We provide real-time, pervasive visibility and insights customers need to accelerate and secure their digital transformation. Our Omnis® cybersecurity advanced threat detection and response platform offers comprehensive network visibility, threat detection, highly contextual investigation, and automated mitigation at the network edge. NETSCOUT nGenius™ service assurance solutions provide real-time, contextual analysis of service, network, and application performance. And Arbor Smart DDoS Protection by NETSCOUT products help protect against attacks that threaten availability and advanced threats that infiltrate networks to steal critical business assets. To learn more about improving service, network, and application performance in physical or virtual data centers or in the cloud, and how NETSCOUT's security and performance solutions can help you move forward with confidence, visit www.netscout.com or follow @NETSCOUT on Twitter, Facebook, or LinkedIn.
©2021 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005395/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
